| Jocelyn Dawn Delp, | |
|
300 S Jefferson St, Kittanning, PA 16201-2416 | |
| (724) 545-4629 | |
| Not Available |
| Full Name | Jocelyn Dawn Delp |
|---|---|
| Gender | Female |
| Speciality | Licensed Vocational Nurse |
| Location | 300 S Jefferson St, Kittanning, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639746134 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164X00000X | Licensed Vocational Nurse | PN305746 (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jocelyn Dawn Delp, 300 S Jefferson St, Kittanning, PA 16201-2416 Ph: (724) 545-4629 | Jocelyn Dawn Delp, 300 S Jefferson St, Kittanning, PA 16201-2416 Ph: (724) 545-4629 |
News Archive
Depomed, Inc. today announced top-line results from a Phase 3 clinical trial demonstrating DM-1796 (also referred to as gabapentin ER) achieved a statistically significant reduction in pain associated with postherpetic neuralgia (PHN) versus placebo using the baseline observation carried forward (BOCF) method required by FDA.
APEIRON Biologics AG, a company focused on cancer immunotherapy, today announced that it will present at Biotech Showcase 2018, to be held January 8–10 at the Hilton San Francisco Union Square during one of the most important weeks in healthcare investing.
Tripping, stumbling, falling, slow, steady loss of muscle control and strength in hands and feet, difficulty speaking, swallowing and breathing...
Synta Pharmaceuticals Corp. today announced that preclinical results presented at the "Bridging the Gap 2010" Hematologic Conference, held in Singapore City, Singapore, February 5-7, 2010, shows that STA-9090, a potent inhibitor of heat shock protein 90 (Hsp90), inhibits the Wilms' tumor 1 (WT1) protein, a key transcription factor that drives disease progression in acute myeloid leukemia (AML) as well as certain other leukemias. STA-9090 is currently enrolling patients in two clinical trials in AML and other hematologic cancers.
Galapagos NV and Sareum Holdings plc has announced today that Galapagos has acquired Sareum's assets in drug discovery services, for a total cash consideration of EUR 695,000 (£553,000). These assets will position Galapagos' service division BioFocus DPI strongly in the growing field of structure-based drug discovery.
› Verified 1 days ago